Song LIU

Dr. Song Liu is the Executive Director of HighLight Capital, a China based healthcare, consumer and technology investment firm. He has more than 8 years of pharmaceutical industry research and healthcare investment experience. Prior to HighLight Capital, Dr. Liu worked at Novartis Institutes for BioMedical Research in Shanghai as an Investigator in Medicinal Chemistry. Dr. Liu's representative deals include Bonti (acquired by Allergan), Zentalis (NASDAQ:ZNTL), Singular Genomics (NASDAQ:OMIC), Kintor Pharmaceutical (HKEX:9939), Imago BioSciences, Cullgen, Lysoway, Immusoft, Inmagene and Hope Medicine. Dr. Liu holds a Ph.D in Chemistry from the University of Chicago, and a B.S. in Chemistry from Peking University in China.